Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, UK
FOSAMAX Once Weekly 70 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Oval white tablets, marked with an outline of a bone image on one side, and ‘31’ on the other. |
Each tablet contains 70 mg alendronic acid (as sodium trihydrate).
Excipients with known effect: Each tablet contains 113.4 mg lactose (as lactose anhydrous).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Alendronic acid |
Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality. |
| List of Excipients |
|---|
|
Microcrystalline cellulose |
Aluminum/aluminum blisters in cartons containing 2, 4, 8, 12 or 40 tablets.
Not all pack sizes may be marketed.
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, UK
PL 00025/0399
10 November 2000/9 November 2005
| Drug | Countries | |
|---|---|---|
| FOSAMAX | Austria, Brazil, Canada, Germany, Spain, France, Hong Kong, Croatia, Ireland, Italy, Mexico, Netherlands, New Zealand, Romania, Singapore, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
